Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Belapectin in Hepatic Impairment
NCT04332432Phase 1Completed
- Sponsor
- Galectin Therapeutics
- Start
- Jun 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belapectin in liver failure (4 arms), sponsored by Galectin Therapeutics. Primary endpoints: Area Under the Curve from Time Zero to Infinity, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 2 more. Started Jun 2020; status: completed.
02
Drugs
belapectin
03
Conditions
liver failure
Beyond the preview
Go deeper on NCT04332432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332432.